Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis par Kelvin K. W. Chan, Helen Guo, Sierra Cheng, Jaclyn M. Beca, Ruby Redmond‐Misner, Wanrudee Isaranuwatchai, Lucy Qiao, Craig Earle, Scott R. Berry, James J. Biagi, Stephen Welch, Brandon M. Meyers, Nicole Mittmann, Natalie Coburn, Jessica Arias, Deborah Schwartz, Wei F. Dai, Scott Gavura, Robin McLeod, Erin D. Kennedy

Accéder au texte intégral